
Defendant Novartis Pharmaceuticals Corporation (“Novartis”) alleged that Plaintiff Plexxikon Inc.’s (“Plexxikon’s”) asserted patent claims are invalid for lack of enablement. When one skilled in the art can practice the claimed invention only after undue experimentation, the claimed invention is invalid